These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 20331473)
1. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge. Gershoni-Yahalom O; Landes S; Kleiman-Shoval S; Ben-Nathan D; Kam M; Lachmi BE; Khinich Y; Simanov M; Samina I; Eitan A; Cohen IR; Rager-Zisman B; Porgador A Immunology; 2010 Aug; 130(4):527-35. PubMed ID: 20331473 [TBL] [Abstract][Full Text] [Related]
2. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. Chu JH; Chiang CC; Ng ML J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111 [TBL] [Abstract][Full Text] [Related]
3. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880 [TBL] [Abstract][Full Text] [Related]
4. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430 [TBL] [Abstract][Full Text] [Related]
5. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF Virol J; 2010 Jul; 7():146. PubMed ID: 20604940 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579 [TBL] [Abstract][Full Text] [Related]
7. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903 [TBL] [Abstract][Full Text] [Related]
9. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys. Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K Virol J; 2015 Apr; 12():54. PubMed ID: 25889682 [TBL] [Abstract][Full Text] [Related]
11. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses. Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007 [TBL] [Abstract][Full Text] [Related]
12. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682 [TBL] [Abstract][Full Text] [Related]
13. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions. Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384 [TBL] [Abstract][Full Text] [Related]
15. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE). Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372 [TBL] [Abstract][Full Text] [Related]
16. Human Monoclonal Antibodies against NS1 Protein Protect against Lethal West Nile Virus Infection. Wessel AW; Doyle MP; Engdahl TB; Rodriguez J; Crowe JE; Diamond MS mBio; 2021 Oct; 12(5):e0244021. PubMed ID: 34634945 [TBL] [Abstract][Full Text] [Related]
17. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine. Quintel BK; Thomas A; Poer DeRaad DE; Slifka MK; Amanna IJ Vaccine; 2019 Jul; 37(30):4214-4221. PubMed ID: 30606462 [TBL] [Abstract][Full Text] [Related]
18. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Hughes HR; Crill WD; Davis BS; Chang GJ Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery. Tinker JK; Yan J; Knippel RJ; Panayiotou P; Cornell KA Toxins (Basel); 2014 Apr; 6(4):1397-418. PubMed ID: 24759174 [TBL] [Abstract][Full Text] [Related]
20. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. Kim S; Li L; McMurtrey CP; Hildebrand WH; Weidanz JA; Gillanders WE; Diamond MS; Hansen TH J Immunol; 2010 Apr; 184(8):4423-30. PubMed ID: 20212098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]